SEC Form 4 · accession 0001209191-17-057218
Orexigen Therapeutics, Inc. · OREXQ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas R Cannell
Officer — EVP, COO, Pres Global Com Prod
Period of report
Oct 13, 2017
Accepted (ET)
Oct 17, 2017 · 7:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001382911
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock Units (RSU)F2,F1,F3 | — | Oct 13, 2017 | A | 91,200 | A | — | — | Common Stock | 91,200 | 91,200 | D |
Explanation of responses
- F1Each RSU represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.
- F2Reflects an award of restricted stock units ("RSUs"), each representing a contingent right to receive a share of the issuer's common stock upon settlement.
- F3Twenty-five percent (25%) of the RSUs will vest on each of the first four (4) anniversaries of February 3, 2018 (each, a "Vesting Date"), subject to the reporting person's continued eligibility on each applicable Vesting Date.